A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Sara A. Hurvitz, Florence Dalenc, Mario Campone, Ruth M. O'Regan, Vivianne C. Tjan-Heijnen, Joseph Gligorov, Antonio Llombart, Haresh Jhangiani, Hamid R. Mirshahidi, Elizabeth Tan-Chiu, Sara Miao, Mona El-Hashimy, Jeremie Lincy, Tetiana Taran, Jean-Charles Soria, Tarek Sahmoud, Fabrice Andre

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)437-446
JournalBreast Cancer Research and Treatment
Volume141
Issue number3
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Advanced breast cancer
  • Everolimus
  • Human epidermal growth factor receptor 2-positive
  • mTOR inhibitor
  • Paclitaxel
  • Trastuzumab resistant

Cite this

Hurvitz, S. A., Dalenc, F., Campone, M., O'Regan, R. M., Tjan-Heijnen, V. C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H. R., Tan-Chiu, E., Miao, S., El-Hashimy, M., Lincy, J., Taran, T., Soria, J-C., Sahmoud, T., & Andre, F. (2013). A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 141(3), 437-446. https://doi.org/10.1007/s10549-013-2689-5